Vagus nerve stimulation, depression, and inflammation

Neuropsychopharmacology

Volumn 32, Issue 9, 2007, Pages 2053-2054

  Das, Undurti N ^a  

^a UND LIFE SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HIGH MOBILITY GROUP B1 PROTEIN; INTERLEUKIN 6; MACROPHAGE MIGRATION INHIBITION FACTOR; TUMOR NECROSIS FACTOR ALPHA;

BRAIN STEM; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DEPRESSION; EFFERENT NERVE; HUMAN; INFLAMMATION; LETTER; MOOD; PRIORITY JOURNAL; PROTEIN EXPRESSION; SEROTONINERGIC SYSTEM; SOLITARY TRACT NUCLEUS; VAGUS NERVE STIMULATION;

DEPRESSION; ELECTRIC STIMULATION; HUMANS; INFLAMMATION; VAGUS NERVE;

EID: 34547882782     PISSN: 0893133X     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.npp.1301286     Document Type: Letter

References (13)

1. Basterzi AD, Aydemir C, Kisa C, Aksaray S, Tuzer V, Yazici K et al (2005). IL-6 levels decrease with SSRI treatment in patients with major depression. Hum Psychopharmacol 20: 473-476.
2. Bernik TR, Friedman SG, Ochani M, DiRaimo R, Ulloa L, Yang H et al (2002). Pharmacological stimulation of the cholinergic antiinflammatory pathway. J Exp Med 195: 781-788.
3. Borovikova LV, Ivanova S, Zhang M, Yang H, Botchkina GI, Watkins LR et al (2000). Vagus nerve stimulation attenuates the systemic inflammatory response to endotoxin. Nature 405: 458-462.
4. Castanon N, Leonard BE, Neveu PJ, Yirmiya R (2002). Effects of antidepressants on cytokine production and actions. Brain Behav Immun 16: 569-574.
5. Dunn AJ, Swiergiel AH, de Beaurepaire R (2005). Cytokines as mediators of depression: what can we learn from animal studies? Neurosci Biobehav Rev 29: 891-909.
6. Guarini S, Altavilla D, Giuliani D, Bigiani A, Marini H, Squadrito G et al (2003). Efferent vagal fibre stimulation blunts nuclear factor-kappaB activation and protects against hypovolemic hemorrhagic shock. Circulation 107: 1189-1194.
7. Levine J, Barak Y, Chengappa KN, Rapoport A, Rebey M, Barak V (1999). Cerebrospinal cytokine levels in patients with acute depression. Neuropsychobiology 40: 171-176.
8. Nemeroff CB, Mayberg HS, Krahl SE, McNamara J, Frazer A, Henry TR et al (2006). VNS therapy in treatment-resistant depression: clinical evidence and putative neurobiological mechanisms. Pscychoneuropharmacology 31: 1345-1355.
9. O'Brien SM, Scott LV, Dinan TG (2004). Cytokines: abnormalities in major depression and implications for pharmacological treatment. Hum Psychopharmacol 19: 397-403.
10. Schiepers OJ, Wichers MC, Maes M (2005). Cytokines and major depression. Prog Neuropsychopharmacol Biol Psychiatry 29: 201-217.
11. Sluzewska A, Rybakowski J, Bosmans E, Sobieska M, Berghmans R, Maes M et al (1996). Indicators of immune activation in major depression. Psychiatry Res 64: 161-167.
12. Suarez EC, Krishnan RR, Lewis JG (2003). The relation of severity of depressive symptoms to monocyte-associated proinflammatory cytokines and chemokines in apparently healthy men. Psychosom Med 65: 362-368.
13. Ulloa L (2005). The vagus nerve and the nicotinic antiinflammatory pathway. Nat Rev Drug Discov 4: 673-683.